GLPBio

Chromatin/Epigenetics

Read More about this category
Chromatin/Epigenetics

Epigenetics

Epigenetics means above genetics. It determines how much and whether a gene is expressed without changing DNA sequences. Epigenetic regulations include, 1. DNA methylation: the addition of methyl group to DNA, converting cytosine to 5-methylcytosine, mostly at CpG sites; 2. Histone modifications: posttranslational modificationEpigeneticss of histone proteins including acetylation, methylation, ubiquitylation, phosphorylation and sumoylation; 3. miRNAs: non-coding microRNA downregulating gene expression; 4. Prions: infectious proteins viewed as epigenetic agents capable of inducing a phenotype without changing the genome.

Research Areas

Products Related to Chromatin/Epigenetics(1791)

  • GC79162 structure
    GC79162NSD2-IN-5
    CAS: 2604513-53-1
    Purity: >98.50%

    NSD2-IN-5 (Compound 198) is a SET domain-containing nuclear protein 2 ( NSD2 ) inhibitor with an IC 50 value ranging from 0.001 μM to 0.01 μM.

  • GC79163 structure
    GC79163UNC6535 TFA
    Purity: >99.00%

    UNC6535 TFA is a covalent ligand targeting the triple Tudor domain (3TD) of SETDB1.

  • GC79164 structure
    GC79164LLC0424N
    CAS: 3063448-59-6
    Purity: >98.00%

    LLC0424 N is a negative control compound designed by methylating the thalidomide moiety of LLC0424.

  • GC79165 structure
    GC79165Snail IN-1
    CAS: 3083216-69-4
    Purity: >98.00%

    Snail IN-1 is an orally active Snail inhibitor with a Ka of 0.36 μM.Snail IN-1 disrupts Snail - CBP interaction, accelerates Snail protein degradation, reduces Snail acetylation, increases Snail polyubiquitination, and selectively downregulates Snail protein without altering other EMT transcription factors.Snail IN-1 reduces atherosclerotic plaque burden, modulates inflammation and plaque stability factors, downregulates CCL5, CXCL10, MMP2, and MMP9, and upregulates α-smooth muscle actin.Snail IN-1 exerts anti-inflammatory and plaque-stabilizing properties.Snail IN-1 can be used for the research of atherosclerosis [1] .

  • GC79167 structure
    GC79167METTL1-WDR4-IN-1 TFA
    Purity: >99.50%

    METTL1-WDR4-IN-1 (Compound 1) TFA is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 ( IC 50 =144 μM).

  • GC79168 structure
    GC79168EP102
    CAS: 3050818-07-7
    Purity: >98%

    EP102 is an orally active, selective inhibitor of the METTL3/METTL14 complex with an IC 50 of 2 nM.

  • GC79169 structure
    GC79169Lepodisiran
    CAS: 2808361-18-2
    Purity: >91.50%

    Lepodisiran (LY3819469) is a GalNAc-conjugated small interfering RNA lipid-lowering agent.

  • GC79170 structure
    GC79170Farabursen sodium
    CAS: 2921918-19-4
    Purity: >93.50%

    Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor.

  • GC79171 structure
    GC79171Farabursen sodium scrambled negative control
    Purity: >96.00%

    Farabursen sodium scrambled negative control is the sequence scrambled negative control of Farabursen sodium.

  • GC79172 structure
    GC79172Mivelsiran sodium
    Purity: >95.00%

    Mivelsiran (ALN-APP) sodium is an siRNA targeting the β-amyloid precursor protein ( APP ).

  • GC79173 structure
    GC79173SH6
    CAS: 2619408-35-2
    Purity: >99.00%

    SH6 is a CRBN -dependent proteasome degrader that targets ZBTB7A.

  • GC79174 structure
    GC79174(S)-NSD2-IN-5
    Purity: >99.50%

    (S)-NSD2-IN-5 is the S-isomer of NSD2-IN-5.

  • GC79178 structure
    GC79178BRD4 degrader-7
    Purity: >98%

    BRD4 degrader-7 (Compound ZZ1) is a CTLH -dependent BRD4 degrader and c-Glue with a DC 50 of 489 nM.

  • GC79179 structure
    GC79179WIZ degrader 8 TFA
    Purity: >99.00%

    WIZ degrader 8 (TFA) is the trifluoroacetic acid of WIZ degrader 8.

  • GC79180 structure
    GC79180YZ-836P
    CAS: 3086041-35-9
    Purity: >98.00%

    YZ-836P is a Protein arginine methyltransferase 5 ( PRMT5 ) targeting agent.

  • GC79181 structure
    GC79181RAI-20
    CAS: 2549180-90-5
    Purity: >98.50%

    RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor ( IC 50 =15.1 and 22.7 nM).

  • GC79182 structure
    GC79182WX-02-43
    CAS: 2929223-36-7
    Purity: >99.50%

    WX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23.

  • GC79183 structure
    GC79183CGN peptide TFA
    Purity: >98.00%

    CGN peptide TFA is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide.

  • GC79184 structure
    GC79184Elebsiran scramble negative control
    Purity: >98.00%

    Elebsiran scramble negative control is the scrambled sequence of Elebsiran, and its modification method is the same.

  • GC79185 structure
    GC79185Vutrisiran sodium scrambled negative control
    Purity: >93.50%

    Vutrisiran sodium scrambled negative control is the sequence scrambled negative control of Vutrisiran sodium.

  • GC79188 structure
    GC79188TAS1440
    CAS: 2098585-77-2
    Purity: >98.00%

    TAS1440 is an orally active LSD1/KDM1A inhibitor with a human IC 50 of 4.8 nM.

  • GC79189 structure
    GC79189Z116334910
    CAS: 412940-42-2
    Purity: >99.00%

    Z116334910 is a promising WDR5-MLL1 interaction disruptor.

  • GC79370 structure
    GC79370PD-L1/HDAC6-IN-1 TFA
    Purity: >99.50%

    PD-L1/HDAC6-IN-1 TFA is an orally active dual inhibitor of PD-L1 and HDAC6, with IC 50 values of 26.8 nM and 78 nM, respectively.

  • GC79451 structure
    GC79451JP-11646
    CAS: 1902983-63-4
    Purity: >98.50%

    JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 ( IC 50 = 0.5 nM).